Literature DB >> 9853519

Behavioral recovery in 6-hydroxydopamine-lesioned rats by cotransduction of striatum with tyrosine hydroxylase and aromatic L-amino acid decarboxylase genes using two separate adeno-associated virus vectors.

D S Fan1, M Ogawa, K I Fujimoto, K Ikeguchi, Y Ogasawara, M Urabe, M Nishizawa, I Nakano, M Yoshida, I Nagatsu, H Ichinose, T Nagatsu, G J Kurtzman, K Ozawa.   

Abstract

Parkinson's disease (PD) is characterized by the progressive loss of the dopaminergic neurons in the substantia nigra and a severe decrease in dopamine in the striatum. A promising approach to the gene therapy of PD is intrastriatal expression of enzymes in the biosynthetic pathway for dopamine. Tyrosine hydroxylase (TH) catalyzes the synthesis of L-dopa, which must be converted to dopamine by aromatic L-amino acid decarboxylase (AADC). Since the endogenous AADC activity in the striatum is considered to be low, coexpression of both TH and AADC in the same striatal cells would increase the dopamine production and thereby augment the therapeutic effects. In the present study, the TH gene and also the AADC gene were simultaneously transduced into rat striatal cells, using two separate adeno-associated virus (AAV) vectors, AAV-TH and AAV-AADC. Immunostaining showed that TH and AADC were coexpressed efficiently in the same striatal cells in vitro and in vivo. Moreover, cotransduction with these two AAV vectors resulted in more effective dopamine production and more remarkable behavioral recovery in 6-hydroxydopamine (6-OHDA)-lesioned rats, compared with rats receiving AAV-TH alone (p < 0.01). These findings suggest an alternative strategy for gene therapy of PD and indicate that the simultaneous transduction with two AAV vectors can extend their utility for potential gene therapy applications.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9853519     DOI: 10.1089/hum.1998.9.17-2527

Source DB:  PubMed          Journal:  Hum Gene Ther        ISSN: 1043-0342            Impact factor:   5.695


  26 in total

1.  Reversal of motor impairments in parkinsonian rats by continuous intrastriatal delivery of L-dopa using rAAV-mediated gene transfer.

Authors:  Deniz Kirik; Biljana Georgievska; Corinna Burger; Christian Winkler; Nicholas Muzyczka; Ronald J Mandel; Anders Bjorklund
Journal:  Proc Natl Acad Sci U S A       Date:  2002-03-26       Impact factor: 11.205

2.  Characterization of anti-HIV activity mediated by R88-APOBEC3G mutant fusion proteins in CD4+ T cells, peripheral blood mononuclear cells, and macrophages.

Authors:  Zhujun Ao; Xiaoxia Wang; Alexander Bello; Kallesh Danappa Jayappa; Zhe Yu; Keith Fowke; Xinying He; Xi Chen; Junhua Li; Gary Kobinger; Xiaojian Yao
Journal:  Hum Gene Ther       Date:  2011-03-18       Impact factor: 5.695

3.  Rescue of hereditary form of dilated cardiomyopathy by rAAV-mediated somatic gene therapy: amelioration of morphological findings, sarcolemmal permeability, cardiac performances, and the prognosis of TO-2 hamsters.

Authors:  Tomie Kawada; Mikio Nakazawa; Sakura Nakauchi; Ken Yamazaki; Ryoichi Shimamoto; Masashi Urabe; Jumi Nakata; Chieko Hemmi; Fujiko Masui; Toshiaki Nakajima; Jun-Ichi Suzuki; John Monahan; Hiroshi Sato; Tomoh Masaki; Keiya Ozawa; Teruhiko Toyo-Oka
Journal:  Proc Natl Acad Sci U S A       Date:  2002-01-22       Impact factor: 11.205

4.  Neuromolecular imaging, a nanobiotechnology for Parkinson's disease: advancing pharmacotherapy for personalized medicine.

Authors:  P A Broderick; L Wenning; Y-S Li
Journal:  J Neural Transm (Vienna)       Date:  2016-10-28       Impact factor: 3.575

Review 5.  Hot topics in adeno-associated virus as a gene transfer vector.

Authors:  N Zhao; D P Liu; C C Liang
Journal:  Mol Biotechnol       Date:  2001-11       Impact factor: 2.695

6.  Adeno-associated virus-mediated transfer of endothelial nitric oxide synthase gene reduces the vasoconstrictive response.

Authors:  Y Maeda; U Ikeda; M Shimpo; S Ishibashi; T Takizawa; J Monahan; K Ozawa; K Shimada
Journal:  Exp Clin Cardiol       Date:  2001

Review 7.  Gene-based vaccines and immunotherapeutic strategies against neurodegenerative diseases: Potential utility and limitations.

Authors:  Jeremy J Kudrna; Kenneth E Ugen
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

Review 8.  Early Parkinson's disease: what is the best approach to treatment.

Authors:  A H Hristova; W C Koller
Journal:  Drugs Aging       Date:  2000-09       Impact factor: 3.923

Review 9.  Tyrosine hydroxylase (TH), its cofactor tetrahydrobiopterin (BH4), other catecholamine-related enzymes, and their human genes in relation to the drug and gene therapies of Parkinson's disease (PD): historical overview and future prospects.

Authors:  Toshiharu Nagatsu; Ikuko Nagatsu
Journal:  J Neural Transm (Vienna)       Date:  2016-08-04       Impact factor: 3.575

10.  Methods, potentials, and limitations of gene delivery to regenerate central nervous system cells.

Authors:  Arvind Kumar; Tryambak D Singh; Santosh K Singh; Satya Prakash
Journal:  Biologics       Date:  2009-07-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.